Interferon alpha hybrid - Alfacyte

Drug Profile

Interferon alpha hybrid - Alfacyte

Latest Information Update: 29 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Strathclyde
  • Developer Alfacyte; University of Edinburgh
  • Class Antiallergics; Antineoplastics; Interferons; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors; Interleukin-22 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Food hypersensitivity

Highest Development Phases

  • Research Cancer; Food hypersensitivity; Psoriasis

Most Recent Events

  • 29 May 2017 Alfacyte has patent protection for interferon alpha hybrid in USA
  • 29 May 2017 Early research in Cancer in United Kingdom (PO) before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top